Advertisement

Pharmacology and Safety of Bismuth Compounds

  • A. Slikkerveer
  • F. A. de Wolff
Conference paper

Abstract

The increasing tendency to administer colloidal bismuth subcitrate (CBS) in the treatment of Helicobacter pylori infections has renewed interest in the therapeutic use of bismuth compounds. Because of the still unexplained, epidemic-like outbreak of poisoning caused by inorganic bismuth compounds in France between 1972 and 1978, interest in its possible toxicity was also revived.

Keywords

High Molecular Weight Protein Proximal Small Bowel Bismuth Compound Proximal Tubulus Bismuth Subcitrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beaver DL, Burr RE (1963) Bismuth inclusions in the human kidney. Archives of Pathology 76:89–94PubMedGoogle Scholar
  2. Buijs WC, Corstens FH, Beentjes LB (1985) Long-term retention of 207Bi in the body after injection of 206Bi. Health Phys 49:1267–1269PubMedGoogle Scholar
  3. Chaleil D, Lefevre F, Allain P, Martin GJ (1981) Enhanced bismuth digestive absorption in rats by some sulfhydryl compounds: nmr study of complexes formed. J Inorg Biochem 15:213–221PubMedCrossRefGoogle Scholar
  4. Coghill SB, Hopwood D, McPherson S, Hislop S (1983) The ultrastructural localisation of De-Nol(®) (colloidal tripotassium dicitrato-bismuthate-TDB) in the upper gastrointestinal tract of man and rodents following oral and instrumental administration. J Pathol 139:105–114PubMedCrossRefGoogle Scholar
  5. Conso F, Bourdon R, Gaultier M (1975) Bismuth sanguin et urinaire après traitement bref par differents sels “insolubles” de bismuth. Eur J Toxicol 8:137–141Google Scholar
  6. De Bray J-M, Emile J, Moreau R, Daver A, Cheguillaume J, Allain P (1977) Pathogénie des encephalopathies bismuthiques. Étude préliminaire à l’aide du bismuth 206 chez l’homme. Nou Presse Med 6:1394Google Scholar
  7. D’Souza RW, Francis WR (1987) Bioavailability and pharmacokinetics of bismuth in the rat. Pharm Res 4 [Suppl]: 115Google Scholar
  8. Gavey CJ, Szeto M-L, Nwokolo CU, Sercombe J, Pounder RE (1989) Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 3:21–28PubMedCrossRefGoogle Scholar
  9. Ghadially FN (1979) Ultrastructural localization and in situ analysis of iron, bismuth and gold inclusions. CRC Crit Rev Toxicol 6:303–350PubMedCrossRefGoogle Scholar
  10. Gregus Z, Klaassen CD (1986) Disposition of metals in rats: a comparative study of fecal, urinary and biliary excretion and tissue distribution of eighteen metals. Toxicol Appl Pharmacol 85:24–38PubMedCrossRefGoogle Scholar
  11. Hespe W, Staal HJM, Hall DWR (1988) Bismuth absorption form the colloidal subcitrate. Lancet II:1258CrossRefGoogle Scholar
  12. Hillemand P, Pallière M, Laquais B, Bouvet P (1977) Traitement bismuthique et bismuthemie. Semaine des Hôpiteaux de Paris 53:1663–1669Google Scholar
  13. Hudson M, Mowat NAG (1989) CBS (De-Nol(®)) self-poisoning - reversible toxicity. Br Med J 299:159CrossRefGoogle Scholar
  14. Lee SP (1981) Studies on the absorption and excretion of tripotassium dicitrato-bismuthate in man. Res Commun Chem Pathol Pharmacol 43:359–364Google Scholar
  15. Lee SP, Lim TH, Pybus J, Clarke AC (1980) Tissue distribution of orally administered bismuth in the rat. Clin Exp Pharmacol Physiol 7:319–324PubMedCrossRefGoogle Scholar
  16. Martin-Bouyer G, Foulon B, Guerbois H, Barin C (1980) Aspects épidémiologiques des encephalopathies apres administration de bismuth par voie orale. Therapie 35:307–313PubMedGoogle Scholar
  17. Martin-Bouyer G, Foulon G, Guerbois H, Barin C (1981) Epidemiological study of encephalopathies following bismuth administration per os. Characteristics of intoxicated subjects: comparison with a control group. Clin Toxicol 18:1277–1283PubMedCrossRefGoogle Scholar
  18. McLean AJ, Froomes P, McNeill JJ, Wan AT, Harrison PM (1988) Bismuth subcitrate handling in man; abstract. Clin Pharmacol Ther 186Google Scholar
  19. Nwokolo CU, Gavey CJ, Smith JTL, Pounder RE (1989) The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 3:29–39PubMedCrossRefGoogle Scholar
  20. Reinicke C (1982) Bismuth. In: Dukes MNG (ed) Dukes side effects of drugs (annual 6), Excerpta Medica, Amsterdam, pp:217–221Google Scholar
  21. Slikkerveer A, de Wolff FA (1989) Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp 4:303–322PubMedGoogle Scholar
  22. Stiel D, Murray DJ, Peters TJ (1985) Uptake and subcellular localisation of bismuth in the gastrointestinal mucosa of rats after short term administration of CBS. Gut 26:364–368PubMedCrossRefGoogle Scholar
  23. Szymanska JA, Piotrowski JK (1980) Studies to identify the low molecular weight bismuthbinding proteins in rat kidney. Biochem Pharmacol 29:2913–2918PubMedCrossRefGoogle Scholar
  24. Szymanska JA, Zychowicz M, Zelazowski AJ, Piotrowski JK (1978) Effect of selenium on the organ distribution and binding of bismuth in rat tissues. Arch Toxicol 40:131–141PubMedCrossRefGoogle Scholar
  25. Thomas DW, Sobecki S, Hartley TF, Coyle P, Alp MH (1983) Variable absorption and excretion of bismuth and its potential for toxicity. In: Brown SS, Savory J (eds) Chemical toxicology and clinical chemistry of metals. Academic, London, pp:391–394Google Scholar
  26. Urizar R, Vernier RL (1966) Bismuth nephropathy. JAMA 198:207–209CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • A. Slikkerveer
  • F. A. de Wolff

There are no affiliations available

Personalised recommendations